Document is current
Any future updates will be listed below
-
Authors
Zylla, Maura M. https://orcid.org/0000-0001-9373-8132
Özdemir, Belgin
Hochadel, Matthias
Zeymer, U.
Akin, Ibrahim
Grau, Armin
Schneider, Steffen
Alonso, Angelika
Waldecker, Bernd
Süselbeck, Tim
Schwacke, Harald
Haass, Markus
Zahn, Ralf
Borggrefe, Martin
Senges, Jochen
Frey, Norbert
Thomas, Dierk
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02978248 at ClinicalTrials.govDocuments that mention this clinical trial
Phenotypes of Patients with Direct Oral Anticoagulant (DOAC) Underdosing in Atrial Fibrillation: Results from the ARENA Registry
https://doi.org/10.1007/s40261-024-01411-w
Community-based analysis of stroke prevention and effect of public interventions in atrial fibrillation: results from the ARENA project
https://doi.org/10.1007/s00392-024-02510-6
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim
Stiftung Institut für Herzinfarktforschung
Deutsche Stiftung für Herzforschung
Universitätsklinikum Heidelberg
- License Information
-
More Information
Article History
Received: 18 January 2024
Accepted: 29 July 2024
First Online: 8 August 2024
Declarations
:
: M.M.Z. reports lecture fees/honoraria and travel support by Medtronic, Boston Scientific, Abbott, Bayer Vital, Pfizer, ZOLL CMS. U.Z. reports lecture fees from AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, Pfizer. J.S. has received honoraria fees for research presentations of ARENA Registry. N. F. reports lecture fees from Astra Zeneca, Bayer Vital, Boehringer Ingelheim, Daiichi Sankyo and Pfizer. D.T. reports receiving lecture fees/honoraria from Abbott, AstraZeneca, Bayer Vital, Boehringer Ingelheim Pharma, Bristol-Myers Squibb, Daiichi Sankyo, Johnson and Johnson Medical, Medtronic, Novartis, Pfizer Pharma, Sanofi-Aventis, and ZOLL CMS.
